Wilson Sonsini Goodrich & Rosati advised Iambic Therapeutics on the transaction. Iambic Therapeutics (Iambic), a clinical-stage biotechnology company, announced the closing of an oversubscribed $50 million...
Iambic Therapeutics’ $50 Million Series B Extension Financing
DermBiont’s $35.2 Million Series B Financing Round
Wilson Sonsini Goodrich & Rosati provided IP and corporate counsel to DermBiont in the transaction. DermBiont announced its $35.2 million Series B financing. The financing was led...
Iambic Therapeutics’ $100 Million Series B Financing Round
Wilson Sonsini Goodrich & Rosati advised Iambic on the transaction. Iambic Therapeutics announced the closing of an oversubscribed $100 million Series B financing. The round was co-led by...